Basics REGENXBIO Inc. Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. IPO Date: September 17, 2015 Sector: Healthcare Industry: Biotech Market Cap: $666.2M Activated in VL: True Average Daily Range Avg Daily Range: $0.77 | 2.89% Avg Daily Range (30 D): $0.33 | 2.76% Avg Daily Range (90 D): $0.31 | 2.97% Institutional Daily Volume Avg Daily Volume: .37M Avg Daily Volume (30 D): .48M Avg Daily Volume (90 D): .5M Trade Size Avg Trade Size (Sh.): 73 Avg Trade Size (Sh.) (30 D): 60 Avg Trade Size (Sh.) (90 D): 63 Institutional Trades Total Inst.Trades: 3,297 Avg Inst. Trade: $1.94M Avg Inst. Trade (30 D): $1.26M Avg Inst. Trade (90 D): $.97M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.19M Avg Closing Trade (30 D): $.9M Avg Closing Trade (90 D): $.82M Avg Closing Volume: 82.05K     News Nov 5, 2025 @ 6:00 PM Choroidal Neovascularization Market to Witness Acc... Source: Delveinsight Oct 6, 2025 @ 3:00 PM Viral Vector Gene Therapy Market Size Expects to R... Source: Towards Healthcare Jul 28, 2025 @ 5:00 PM Duchenne Muscular Dystrophy Market to Witness Sign... Source: Delveinsight May 21, 2025 @ 10:00 AM Coave Therapeutics Establishes New Scientific Advi... Source: N/A Mar 4, 2025 @ 3:55 PM 2025 Market Prospects of Adeno-Associated Virus Ve... Source: Researchandmarkets.Com Financials   TTM Q3 2025 Q2 2025 Basic EPS $-3.46 $-1.2 $-1.38 Diluted EPS $-3.46 $-1.2 $-1.38 Revenue $ 161.32M $ 29.73M $ 21.36M Gross Profit $ $ $ Net Income / Loss $ -177.92M $ -61.94M $ -70.87M Operating Income / Loss $ -154.93M $ -52.41M $ -63.28M Cost of Revenue $ $ $ Net Cash Flow $ 2.19M $ -20.76M $ -50.55M PE Ratio